Insulin Lispro Sanofi

Insulin lispro, the active ingredient in Insulin Lispro Sanofi, is a rapid‑acting insulin analog presented as an injection for subcutaneous use. It treats hyperglycaemia in both type 1 and type 2 diabetes mellitus. GNH USA supplies Insulin Lispro Sanofi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Insulin lispro is a rapid‑acting insulin analog used to control blood glucose in diabetes mellitus.

Type 1 diabetes mellitus: improves post‑prandial glucose control and helps achieve target HbA1c. Type 2 diabetes mellitus: provides mealtime insulin coverage when combined with basal insulin or oral agents.

Insulin lispro may cause a range of adverse reactions.

Common Side Effects: - Hypoglycaemia: low blood glucose episodes, especially if meals are missed. - Injection‑site reactions: redness, swelling, or itching at the injection site. - Lipodystrophy: localized changes in fat tissue with repeated injections. - Weight gain: modest increase due to improved glucose utilisation. - Nausea or mild gastrointestinal discomfort. - Headache.

Serious or Rare Side Effects: - Severe hypoglycaemia leading to loss of consciousness or seizures. - Anaphylactic reaction: hives, swelling, difficulty breathing. - Serum sickness‑like reaction: fever, rash, arthralgia. - Edema: swelling of extremities. - Hypokalemia: low potassium levels. - Acute allergic dermatitis.

When using insulin lispro, several safety considerations apply.

Monitor blood glucose regularly: adjust dose based on readings and meal patterns. Avoid dosing during active hypoglycaemia: treat low blood sugar before administering. Adjust dose in renal or hepatic impairment: reduced clearance may increase risk of hypoglycaemia. Use caution in pregnancy and lactation: safety data are limited; consult a specialist. Educate patients on recognising hypoglycaemia symptoms and appropriate treatment. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insulin lispro can interact with other medicines, altering glucose control.

Major Interactions (Avoid): - Alcohol: potentiates hypoglycaemia, especially with rapid‑acting insulin. - Beta‑blockers: may mask hypoglycaemia symptoms, delaying recognition. - Other insulin products: concurrent use can cause excessive insulin effect.

Moderate Interactions (Monitor Closely): - Sulfonylureas and meglitinides: additive glucose‑lowering effect, increase hypoglycaemia risk. - MAO inhibitors: may enhance insulin’s glucose‑lowering action. - Corticosteroids: can raise blood glucose, requiring dose adjustments.